Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma

This observational study collects and analyses data from patients with hepatocellular carcinoma (HCC, the most common type of primary liver cancer) who received "conversion" or "neoadjuvant" therapy — treatment given before surgery to shrink the tumor enough to make curative surgery possible. **You may be eligible if...** - You have a confirmed diagnosis of liver cancer (HCC), either by biopsy or clinical criteria - You received pre-surgical treatment such as HAIC (chemo infused into liver arteries), TACE (targeted chemo embolization), targeted therapy (TKIs), immunotherapy, or radiation therapy as your initial treatment - Your general health score (ECOG) is 0 or 1 - Your liver function score (Child-Pugh) is between 5 and 7 - You have at least 3 months of follow-up data available **You may NOT be eligible if...** - You have had another active cancer in the past 5 years - Your medical records are incomplete - Your follow-up time is less than 3 months Talk to your doctor to see if this trial is right for you.